Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

Jan Joseph Melenhorst

faculty photo
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
Education:
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, 1988.
MS (Medical Biology)
Nijmegen Katholic University, 1991.
PhD (Immunology)
Leiden University, 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons, Stefan Lundh, Shannon A. Carty, Tyler Reich, Alexandria P. Cogdill, Jennifer J.D. Morrissette, Jamie E. DeNizio, Shantan Reddy, Young Hwang, Mercy Gohil, Irina Kulikovskaya, Farzana Nazimuddin, Minnal Gupta, Fang Chen, John K. Everett, Katherine A. Alexander, Enrique Lin-Shiao, Marvin H. Gee, Xiaojun Liu, Regina M. Young, David Ambrose, Yan Wang, Jun Xu, Martha S. Jordan, Katherine T. Marcucci, Bruce L. Levine, K. Christopher Garcia, Yangbing Zhao, Michael Kalos, David L. Porter, Rahul M. Kohli, Simon F. Lacey, Shelley L. Berger, Frederic D. Bushman, Carl H. June, and J. Joseph Melenhorst: Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-targeted T-cells. Nature. 2018 May 30. doi: 10.1038/s41586-018-0178-z. [Epub ahead of print] June 2018.

Joseph A. Fraietta1,2,3, Simon F. Lacey1,2,3*, Elena J. Orlando4,*, Iulian Pruteanu-Malinici4, Mercy Gohil2, Stefan Lundh2, Alina C. Boesteanu2, Yan Wang2, Roddy S. O’Connor2, Wei-Ting Hwang5, Edward Pequignot2, David E. Ambrose2, Changfeng Zhang2, Nicholas Wilcox2, Felipe Bedoya2, Corin Dorfmeier2, Fang Chen2, Lifeng Tian2, Harit Parakandi2, Minnal Gupta2, Regina M. Young2, F. Brad Johnson1, Irina Kulikovskaya2, Li Liu2, Jun Xu2, Sadik H. Kassim4, Megan M. Suhoski-Davis2, Bruce L. Levine1,2, Noelle V. Frey2,6, Donald L. Siegel1,2,7, Alexander C. Huang3,8, E. John Wherry3,8, Hans Bitter4, Jennifer L. Brogdon4, David L. Porter1,6, Carl H. June1,2,3 and Jan J. Melenhorst1,2,3,‡: Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T cell Therapy of Chronic Lymphocytic Leukemia Nature Medicine 24(5): 563-571, May 2018.

Xu J, Melenhorst JJ, Fraietta JA.: Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy 20(5): 623-638. May 2018.

Kong W, Lacey SF, Melenhorst JJ, Fraietta JA.: Biomarkers in chimeric antigen receptor T-cell therapy. Biomark Med. 12(5): 415-418, May 2018.

Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL, Gostick E, Melenhorst JJ, Barrett AJ, Price DA, Mustjoki S, Wooldridge L.: Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions. Sci Rep 8(1): 2534, Feb 2018.

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH.: Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Mol Ther. 26(1): 269-279, Jan 2018.

Guedan S, Posey AD Jr., Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.: Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight Epub ahead of print, 2018.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Dwivedy Nasta A, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood (Epub ahead of print) 2018.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.: Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther [Epub ahead of print], 2018.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight [Epub ahead of print], 2018.

back to top
Last updated: 06/20/2018
The Trustees of the University of Pennsylvania